Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Salarius Pharmaceuticals ( (SLRX) ) has issued an update.
On September 4, 2025, Salarius Pharmaceuticals announced it had regained compliance with Nasdaq’s minimum bid price requirement, a key step in meeting all Nasdaq listing standards. The company will be monitored for a year to ensure continued compliance. Additionally, Salarius is working on a merger with Decoy Therapeutics, which is expected to enhance its pipeline with innovative peptide conjugate therapeutics targeting respiratory diseases and GI cancers. The merger aims to leverage Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 into new drug candidates, potentially impacting the biopharmaceutical landscape.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients with limited options. Their product portfolio includes seclidemstat, under study for hematologic cancers, and SP-3164, an oral small molecule protein degrader. Salarius has received support from organizations like the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas.
Average Trading Volume: 250,817
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.4M
See more data about SLRX stock on TipRanks’ Stock Analysis page.